Telemedicine technologies and services allow today's ophthalmic clinicians to remotely diagnose, manage and monitor several ophthalmic conditions from a distance. But is this the case for glaucomas? There has been a proliferation of telemedicine friendly devices in recent years that improves the capabilities of the clinician in managing glaucomas. The existing instruments still need to align themselves with accepted industry standards. There are successful programmes running in several areas of the world. The safety and efficacy of these programmes needs further exploration. The inability of a single device or test to diagnose glaucomas satisfactorily has also hampered progress in remotely diagnosing these conditions. There is, however, significant potential for telemedicine-friendly devices to remotely monitor the progress of glaucoma and, thereby, reduce some of the workload on an overstretched health service.
- Remote Consultation
- Optical Coherence
- Intraocular Pressure
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
Statistics from Altmetric.com
Telemedicine, or telehealth, refers to the practice of medicine at a spatial and/or temporal distance by exchanging medical information via electronic communications.1 The key aspect in the development of telemedicine is the constantly evolving interaction between medicine and information and communication technology (ICT). Given that ICT can support data collection and exchange, this can enable improved communication and integration of clinical services. Radiology has been at the vanguard of telemedicine; electronic transfer of digital images between radiological departments is now standard practice because the images do not diminish in quality with transfer.
Telemedicine principles have already been successfully applied within ophthalmology in the National Health Service Diabetic Retinopathy Screening Programme and retinopathy of prematurity screening. A ‘store and forward’ approach is used whereby images/data acquired at one site are transferred to a remote grader who views these images at a different time. Alternative approaches include remote monitoring and interactive telemedicine where self-testing allows clinicians to monitor a patient, and real-time interaction may occur between the clinician and the patient.
Glaucoma management increasingly involves use of devices that are perceived to be ‘telemedicine-friendly’. Automated perimetry, tonometry, corneal pachymetry, imaging of the optic disc, nerve fibre layer and anterior segment, may all generate digital outputs that can be transferred electronically and viewed remotely.
This review outlines the validity of remote review with current technology and work reported to date using remote technology in glaucoma detection and management. Papers included in this review were identified through pubmed searches using the keywords ‘teleophthalmology’, ‘teleglaucoma’, ‘glaucoma imaging’, ‘glaucoma screening’, ‘glaucoma case detection’, ‘glaucoma progression’ and ‘IOP measurement’; references in English were included.
Technology: standardisation and integration
For any telemedicine/telehealth system to be implemented it is vital that open information exchange standards are used. Table 1 illustrates the principal standards and associated organisations that exist in this field.
While some glaucoma devices can already be configured to automatically upload data in a standardised format, others cannot (eg, older Goldmann applanation tonometers and corneal pachymeters). Standardised digital interfaces for most monitoring devices are awaited, and until such point, manual data entry into the electronic patient record will be required.
Political climate and rationale for teleglaucoma
In general, regulatory, legal and financial issues are all barriers to adoption of telehealth. The political momentum in the UK supporting ‘telehealth’ is strong, with the prime minister, David Cameron, pledging that up to 3 million people with chronic conditions will be managed using telehealth technology, funded through the government's Life Sciences Strategy.15 The principal cited reason was the success of the Whole Systems Demonstrator (WSD) trial. This was a cluster randomised trial conducted in 3230 people with diabetes, chronic obstructive pulmonary disease and heart failure.16 Subjects randomised to the telehealth arm underwent home self-monitoring during allotted sessions using instruments, such as glucometers, pulse oximeters, weighing scales and symptom questionnaires. This approach led to a lower 12-month admission rate and mortality at 12 months. Recently, however, doubts have been raised as to whether the strategy was cost effective when compared with standard care.17
Primary open-angle glaucoma (POAG) is a chronic condition with a prevalence of 2% in people over 40 years of age,18–22 rising to over 10% in some populations over 80 years of age.22 ,23 There is a significant burden of disease, with up to 10% of UK blind registrations being attributable to glaucomas.24 Hospital eye services are considerably challenged by the influx of new glaucoma referrals, while continuing to monitor existing stable patients. There is, therefore, an argument to try and minimise hospital visits by reviewing stable glaucoma patients outside the hospital clinic setting.
Most reported teleglaucoma schemes have been used in remote areas where specific glaucoma expertise is not available.25–27 The number of staff at a remote site can be minimised, with potentially a ‘dedicated’ technician overseeing tonometry, imaging and perimetry at each testing station. Any potential teleglaucoma scheme's management team will need to devise a specific training programme and competency assessments (along with continuing education and appraisal) for any staff undertaking testing at a remote site.
Intraocular pressure measurement
Therapies for glaucomas are predominantly focused on lowering intraocular pressure (IOP), hence, this is a crucial element of any follow-up assessment. For detection of disease, IOP measurements above 21 mm Hg have a reported sensitivity of 47% and specificity of 92% for detecting POAG, and this does not improve when confined to high-risk groups.28
Goldmann applanation tonometry (GAT) is now available with a digital output (AT 900D, Haag-Streit International, Koeniz, Switzerland). Non-contact tonometers (NCT), rebound tonometers (iCare, Helsinki, Finland) and hand-held applanation tonometers (Tonopen, Reichert, Depew, New York, USA) have the advantage that less skilled operators can use them effectively, and they are portable. Repeated measurements with GAT are, however, more reproducible than automated methods of IOP measurement.29 Non-contact methods may be subject to systematic bias (rebound tonometry was found to overestimate IOP by a mean of 2.3 mm Hg30 up to 3.4 mm Hg31 compared to GAT) non-systematic bias (there is a tendency for tonopen to underestimate IOP at high IOP levels32–35) and other sources of bias (pneumotonometry and rebound tonometry are prone to overmeasurement with increasingly thicker corneas31 ,36 ,37). However, recent studies have shown marked improvement in measurements between rebound tonometers and GAT.38
Since the management of IOP is relative in each individual, provided the same method of assessment is used for comparison, systematic bias should be of less importance. Of greater importance is non-systematic bias and the reproducibility of results. Automated measurement devices are not necessarily interchangeable substitutes for GAT.
In due course, home monitoring may become a possibility. iCare ONE has been developed specifically for home use.39 ,40 There is also a contact lens sensor device for measuring IOP (Sensimed Triggerfish CLS, Sensimed AG, Lausanne, Switzerland).41 A systematic review and meta-analysis of studies comparing GAT with other tonometers revealed that NCT had the least amount of variability in measurements, and the Ocuton-S (an applanation ‘self’ tonometer) had the lowest agreement with GAT.42 The review also showed that rebound tonometers had better agreement with GAT than Ocuton-S, but still lower than NCT. They identified the need for further evidence comparing tonometers and standardisation of reporting to better assess the results of studies. Ocuton S*TT-MV, a reconfigured version of the Ocuton S has apparent improved functionality.43 However, there remains an inconsistent range of differences in measurement as compared with GAT among patients performing self-tonometry.43 ,44 Other innovations enabling self-tonometry are currently under development.45 ,46 In future, adaptations to smartphones may enable patients to automatically record their IOP and transmit the data to clinicians.47
Optic disc and retinal nerve fibre layer imaging
Since glaucomas are progressive optic neuropathies it is imperative that teleglaucoma strategies should employ a method for structural (optic disc and/or nerve fibre layer) assessment. Stereoscopic disc images have been regarded as the reference standard for clinical trials in glaucoma where a high degree of reproducibility has been achieved using dedicated reading centres.48 Bergua et al49 have demonstrated that stereoscopic optic disc images may be transferred via the internet using a personal computer equipped with stereoscopic liquid crystal display shutter glasses, or using an LCD display in combination with red-cyan goggles for viewing.
Subjective interpretation of optic disc stereophotographs can be highly variable. In a study of sequential stereophotographs, three expert glaucoma specialists could only achieve a ‘slight to fair’ agreement as regards structural progression.50 In a study of European ophthalmologists, asked to assess stereoscopic slides from healthy and glaucoma eyes, an overall ‘diagnostic accuracy’ of 80.5% was achieved.51 In that study, the best performing algorithms for the Heidelberg Retina Tomograph (HRT) (Heidelberg Engineering, Heidelberg, Germany) and GDx (Carl Zeiss Meditec, Dublin, California, USA) generally outperformed most clinicians in terms of diagnostic accuracy. Appropriate training or engagement of a reading centre, should be considered if stereophotographs are to be used in a teleglaucoma scheme.
HRT and optical coherence tomography: glaucoma ‘classification’
The pre-eminent imaging modalities in glaucoma are confocal scanning laser ophthalmoscopy (CSLO, as performed using the HRT) and optical coherence tomography (OCT). A third modality, scanning laser polarimetry (GDx and its derivatives, Carl Zeiss Meditec, Dublin, California, USA), is as effective in terms of glaucoma ‘classification’ as HRT and OCT, but has largely been superseded by OCT technology in terms of clinical practice and in active research.
HRT uses two classification algorithms—the Moorfields Regression Analysis (MRA) and the Glaucoma Probability Score (GPS). MRA is based on the understanding that rim area varies with disc size, may decline with advancing age and may narrow in any sector of the disc in glaucoma. Very large and very small discs confound MRA.52 ,53 Atypical optic nerve head (ONH) morphology may lead to such discs falling outside the normative range without necessarily being glaucomatous. Sensitivities of 58–84% and specificities of 81–96% have been reported depending on inclusion and cut-off criteria.54–56
GPS uses a mathematical model of ONH shape to discriminate between normal and glaucomatous eyes.57 The method is operator-independent as it does not require contour line placement. GPS does not confer any advantage over the MRA in terms of sensitivity and specificity.52 ,58 There is a dependency on disc size for MRA and GPS classification.52
Several studies have demonstrated the performance of time domain OCT (TDOCT) in discriminating between normal and glaucomatous eyes.59–66 Comparisons between TDOCT, CSLO and scanning laser polarimetry have failed to identify a significant advantage of one device over another.61 ,63 ,67 A comparison between the retinal nerve fibre layer (RNFL), ONH and macular thickness parameters of the STRATUSOCT (Carl Zeiss Meditec) found that RNFL thickness and optic nerve head parameters had similar performance in differentiating between healthy and glaucomatous eyes and both outperformed macular thickness parameters.60 In all these studies, performance was assessed using well-defined case controls with established repeatable glaucomatous visual field defects, a scenario that is much more clear-cut than is usually encountered in the normal clinical setting.
A large number of studies have now assessed the ‘diagnostic’ capability of the more recently available spectral domain OCT (SDOCT) devices, and most of these have made a comparison with the performance of TDOCT.68–75 In all cases, SDOCT has been found to have a good diagnostic capability but no major advantage over TDOCT.68 ,71–75
The macula contains approximately 50% of all retinal ganglion cells,76 hence macular thickness may be useful for glaucoma diagnosis.77 ,78 The RNFL, the ganglion cell layer and the inner plexiform layer together make up the ganglion cell complex (GCC). GCC has significantly higher diagnostic power than macular thickness as measured by SDOCT or TDOCT, and the best performing GCC parameters have been found to be equivalent to mean RNFL thickness as measured by TDOCT.79 ,80
OCT technology is now also used widely for the assessment of the anterior segment, and this could potentially be used as a proxy test for gonioscopy. OCT cannot pick up features, such as peripheral anterior synechiae, neovascularisation or pigmentation that are detectable by gonioscopy.
HRT and OCT: monitoring change
The current HRT3 software features two progression algorithms, trend analysis and topographical change analysis (TCA). Interpretation of the trend is empirical and a ‘rate’ of change cannot be generated. The importance of estimating a rate of change is highlighted by the results of the CSLO Ancillary Study to the Ocular Hypertension Treatment Study.81 A five times faster rate of rim loss was identified in eyes converting to glaucoma than those that did not. TCA assesses progression by measuring changes in the height of superpixels generating a ‘change probability map’ with red pixels representing significant height depression.82 TCA tends to identify more subjects as progressing than stereophotographic assessment.83 TCA has also been shown to be predictive of future visual field damage.84
The rapidity by which OCT technology is evolving means there are a few longitudinal studies investigating progression.85–88 In teleglaucoma, it may therefore be preferable to employ stereophotographs and a semiautomated imaging technology. Stereophotographs are largely ‘future-proof’, but they lack automated quantification and progression algorithms, of which HRT TCA is the most mature and well established.
Static automated perimetry (SAP) is the most widely accepted functional test for the evaluation of glaucoma. SAP invariably requires a degree of patient learning for reliable performance and it is time consuming, even when using the Swedish Interactive Thresholding Algorithm (SITA). Ideally, for teleglaucoma purposes, a functional test should be easy to use and quick in order to maintain a high throughput. Objective (electrodiagnostic) perimetry would, therefore, be impractical. Frequency doubling technology (FDT), however, may offer a realistic alternative to SAP. Studies report sensitivities for FDT of between 35% and 93% in early to moderate glaucoma, greater than 97% in severe glaucoma, with a specificity of 90% for early glaucoma and greater than 97% for advanced disease.89–91 FDT may detect glaucomatous visual field loss earlier than SAP,92 but learning effect remains a problem in subjects without prior perimetric experience.93 Despite these advantages, SAP's smaller test-retest variability and larger dynamic range make it currently the optimal choice for monitoring glaucomatous visual field progression.94 Some newer perimetric techniques, such as the Moorfields Motion Displacement Test, are being developed for use on multiple computer monitor platforms.95 It is conceivable that perimetry will become available for use in the domiciliary setting.
Clinicians are much better at detecting field progression when their decision making is augmented by using a computer algorithm.96 Event analyses ascribe progression when a predetermined threshold has been achieved. The native event analysis for the Humphrey Field Analyser (HFA, Carl Zeiss Meditec, Dublin, California, USA), Guided Progression Analysis (GPA), is based on the strategy used in the Early Manifest Glaucoma Treatment study.97 Trend analyses monitor the behaviour of a specific parameter over time, allowing a rate of change to be calculated. A ‘global’ trend analysis, that monitors change in the visual field index (VFI) over time, is included in the GPA package. An alternative approach is to perform pointwise linear regression analysis which is the technique adopted by PROGRESSOR (Medisoft, Leeds, UK). Trend analyses provide better receiver operator characteristic curves than event analyses.98 From a teleglaucoma perspective, there is a good argument for adopting external software, such as PROGRESSOR, as analysis is performed on a different computer from the perimeter following data transfer. This overcomes the issue of lack of Digital Imaging and Communication in Medicine (DICOM) compatibility when using older perimeters.
Teleglaucoma in practice
In glaucoma management and case detection, the outcome of most interest is the number of false negatives, that is, the number of those who are true cases or are progressing cases that are not detected. Detection of false negatives is a major challenge. Both outcomes are relatively rare. The normal methodology to approach such a scenario is to undertake studies determining the sensitivity and specificity using an enriched population. Sensitivity and specificity are independent of prevalence, therefore, improved estimates may be obtained by having large proportions of outcomes of interest in the study group. There is a notable lack of such assessments, meaning that there is a risk of accepting an unsafe system. If glaucoma has a prevalence of 2%, screening 6000 would yield 120 cases. Were only 80 cases detected, the system could be hailed a success, and yet, there are 40 cases undetected. A major factor in favour of decreasing false negatives in chronic disease screening is the opportunity for a ‘second bite at the cherry’ with repeat screening over time. All these issues are, as yet, inadequately explored. The proportion of false positives is also of interest, but much more easily determined.
There are a few published reports of teleglaucoma applied to routine care. The first reported teleglaucoma pilot study was undertaken in Finland, a country where large remote areas have had a chronic lack of ophthalmologists.25 The study used a video slit lamp, an automated perimeter and a non-mydriatic fundus camera, with real-time videoconferencing. A group in Canada has recently described a strategy to service people with, or at risk of, glaucoma in the rural setting and living near the university eye centre.26 The authors describe four main components to their service: enthusiastic staff, secure reliable software, appropriate hardware (a minimum of retinal camera, IOP, central corneal thickness and either FDT or HFA), and national guidelines for glaucoma management. Huatala and colleagues describe a teleophthalmology mobile unit that provides diabetic retinopathy screening and follow-up of stable glaucoma patients in Northern Finland.27 Patients undergo visual field testing using HFA and digital fundus photography. A nurse measures IOP and compares the measurement to a preset target. Images and visual fields are assessed offline by the glaucoma specialist. Online help is available by telephone. A similar approach is being applied within the UK in urban and rural centres. The Newmedica glaucoma service began at Bristol Eye Hospital in 2007 and has provided nearly 100 000 glaucoma review appointments to date from eight mobile sites. The service uses a proprietary electronic medical record software called Electronic Medical Management Application (EMMA), which allows online virtual reviewing over a secure internet connection. An optometrist and two technicians man each mobile clinic. The patient has visual acuity and HFA data collected. The optometrist then takes a history, examines the patient (including pachymetry and GAT), and acquires a dilated fundus photograph (monoscopic) or HRT image. All data are uploaded into EMMA including archive fields and disc images. At the end of the consultation, the optometrist provides a provisional management outcome made final within five working days after review of the data online by a glaucoma specialist working online in a virtual clinic. Once the outcome has been decided, the clinic software automatically writes to the patient and their general practitioner, and the next appointment is booked.
Detection of new cases
A systematic review of diagnostic tests for glaucoma failed to identify a particular advantage of a single test for the purposes of glaucoma screening.99 Indeed, a Health Technology Assessment suggested that screening for open-angle glaucoma would not be cost effective although targeted screening of subjects in high-risk groups (eg, family history, black ethnicity) might be worthwhile.100 A number of groups have tried to apply a targeted approach to glaucoma screening using teleglaucoma.
In Rotterdam, 10 community optometric practices were equipped with GDx, and patients considered ‘at risk’ were offered imaging.101 The images and clinical details were transferred to the eye hospital for assessment. From 1729 patients screened, 467 (27%) were called to the hospital and 80 new cases of glaucoma were identified giving a positive predictive value of only 18%. In a study undertaken in Tasmania, visual acuity, autorefraction, SAP, IOP measurement using the Tonopen and stereoscopic disc photographs were all acquired at remote sites then amalgamated into a summary PDF file that was transferred electronically to a glaucoma specialist.102 First-degree relatives of patients with a confirmed diagnosis of glaucoma were screened and one new case of glaucoma was identified for every 19 participants. There was, however, a very low take-up of the scheme among subjects at risk.
Glaucoma data archiving
Managing glaucoma patients via a remote clinic necessitates the electronic archiving of historic clinical data, including visual fields and images. Visual field data and images can be electronically assimilated into the teleglaucoma notes relatively easily. However, archiving paper notes can present a significant problem where the patient population has been under the care of a clinic for many years, and where paper notes are commensurably bulky. Three potential methods for incorporating historic notes into a paperless teleglaucoma clinic include:
To make historic paper notes available for the first few visits to the teleglaucoma clinic to allow an overlap, whereby the teleglaucoma notes progressively replace the paper notes (which are eventually archived).
To make a full electronic copy of the paper notes and incorporate that archive into the teleglaucoma notes (usually in the form of PDF documents).
To manually transcribe a summary of the salient events from the paper history into the electronic notes.
Each approach represents a compromise. Even the option of scanning the old notes in their entirety can overload the teleglaucoma clinic with data which can be hard to identify and is often of minimal value.
Another area where telehealth may be useful is in postsurgical management. Crowston et al103 assessed the interobserver agreement for clinical signs in post-trabeculectomy eyes when evaluated by real-time video images compared with face-to-face consultation. Remote assessment provided high levels of agreement for bleb vascularity, anterior chamber depth, and the existence of a bleb leak; it was much more variable for bleb height and bleb wall thickness. More recently, a Japanese group has similarly shown images acquired using a remote controlled slit lamp to be of use in postoperative management.104
Glaucomas remain enigmatic conditions in which a diagnosis cannot consistently be made using a single test, or indeed a battery of tests. The proliferation of teleglaucoma-‘friendly’ devices, for IOP measurement and quantitative disc assessment have not necessarily increased our ability to detect glaucomas in the absence of a face-to-face consultation. In that regard, teleglaucoma is perhaps not yet ‘ready to go’. These technologies are, however, likely to be useful in the monitoring of patients with an established diagnosis of glaucoma, and it is in this context that a few teleglaucoma schemes have already become successfully established. Given the increasing age of the population, and the constraints upon already stretched hospital eye services, it is likely that reliance on teleglaucoma will increase. This may be despite the fact that the diagnostic and monitoring capabilities of currently available technologies will not necessarily meet the ambitions of the teleglaucoma schemes from the outset. There is a strong case for further robust studies investigating the positive and negative predictive power of all systems of glaucoma detection and monitoring.
NGS acknowledges a proportion of his financial support from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.
Contributors NGS provided critical revision, original draft, interpretation, oversight and final draft. GC provided original draft, concept revision, oversight and final version. JPD provided critical revision, draft oversight and final draft. IEM provided concept, revising several drafts, oversight and final version. He is guarantor.
Competing interests NGS has received lecture fees from Heidelberg Engineering and MSD as well as author and lecture fees from Allergan. He is an unpaid medical adviser to Moorfields Pharmaceuticals. JPD is Medical Director of New Medical Systems ltd (Newmedica) which provides Glaucoma follow-up via Virtual Clinic service.
Provenance and peer review Not commissioned; externally peer reviewed.